title: SCOPA-AUT scale in different parkinsonisms and its correlation with (123) I-MIBG cardiac scintigraphy.
abstract: BACKGROUND
  Our objective was to assess the usefulness of the Scales for Outcomes in Parkinson's disease - Autonomic (SCOPA-AUT) in the differential diagnosis of Parkinsonisms and clarify its relation with 123-I-MIBG cardiac scintigraphy.
  
  
  METHODS
  A total of 112 patients with Parkinson's disease (PD), 12 with multiple system atrophy parkinsonian variant (MSA-P) and 20 with progressive supranuclear palsy (PSP) participated in the study. The following variables were collected: age, sex, age at onset, length of illness, type and dose of anti-Parkinson medication, and score on the Unified Parkinson's Disease Rating Scale. The Unified Multiple System Atrophy Rating Scale was administered to patients with MSA and the Progressive Supranuclear Palsy Rating Scale to those with PSP. Finally, the SCOPA-AUT was administered to all the patients. Cardiac 123I-MIBG SPECT scans were performed on a subset of patients (25 with PD and 5 with MSA-P).
  
  
  RESULTS
  Statistically significant differences were observed (p < 0.01) in the SCOPA-AUT scores between patients with PD (14.75+/-8.09) and those with MSA (21.07+/-5.56), the latter having higher scores on the bowel function (20.07+/-13.40 vs 34.92+/-14.91) and urinary domains (30.21+/-21.55 vs 49.26+/-21.40) (p < 0.01). No correlation was found between the SCOPA-AUT score and anti-Parkinson's medication and heart:mediastinum (H/M) MIBG uptake ratio in the cardiac SPECT (at 4 h).
  
  
  CONCLUSIONS
  Severity of dysautonomia as measured by the SCOPA-AUT was not correlated with clinical severity, time since onset or the H/M ratio. In the patients with PD, the only variable associated with the H/M ratio was age at onset of the disease.
authors: Service of Neurology, Hospital of Cruces, Plaza de Cruces S/N, 48903 Bilbao, Spain. Koldo_ber@hotmail.com
authors: Koldo
authors: K
authors: Berganzo
authors: Beatriz
authors: B
authors: Tijero
authors: Johanne H
authors: JH
authors: Somme
authors: Verónica
authors: V
authors: Llorens
authors: Juan C
authors: JC
authors: Sánchez-Manso
authors: David
authors: D
authors: Low
authors: Valeria
authors: V
authors: Iodice
authors: Ekawat
authors: E
authors: Vichayanrat
authors: Christopher J
authors: CJ
authors: Mathias
authors: Elena
authors: E
authors: Lezcano
authors: Juan J
authors: JJ
authors: Zarranz
authors: Juan C
authors: JC
authors: Gómez-Esteban
mesh_terms: D019797:3-Iodobenzylguanidine; D000368:Aged; D003937:Diagnosis, Differential; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008482:Mediastinum / Q000000981:diagnostic imaging*; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000175:diagnosis / Q000000981:diagnostic imaging*; D010300:Parkinson Disease / Q000175:diagnosis / Q000000981:diagnostic imaging*; D020734:Parkinsonian Disorders / Q000175:diagnosis / Q000000981:diagnostic imaging; D012720:Severity of Illness Index; D013494:Supranuclear Palsy, Progressive / Q000175:diagnosis / Q000000981:diagnostic imaging*; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods / Q000592:standards
chemical_list: D019797:3-Iodobenzylguanidine